Viking Therapeutics Inc
VKTX
Company Profile
Business description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Contact
9920 Pacific Heights Boulevard
Suite 350
San DiegoCA92121
USAT: +1 858 704-4660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
What next for the largest company on the ASX?
After a historic rally in 2024, what lies ahead for this overvalued banking titan?
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,013.30 | 46.70 | 0.59% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,813.57 | 537.36 | -1.30% |
| FTSE 100 | 8,542.56 | 1.59 | 0.02% |
| HKSE | 24,039.04 | 576.39 | 2.46% |
| NASDAQ | 17,303.01 | 345.44 | -1.96% |
| Nikkei 225 | 37,053.10 | 263.07 | 0.72% |
| NZX 50 Index | 12,266.25 | 57.20 | 0.47% |
| S&P 500 | 5,521.52 | 77.78 | -1.39% |
| S&P/ASX 200 | 7,789.70 | 40.60 | 0.52% |
| SSE Composite Index | 3,418.05 | 59.32 | 1.77% |